Protein aggregation: From background to inhibition strategies

被引:138
作者
Alam, Parvez [1 ]
Siddiqi, Khursheed [1 ]
Chturvedi, Sumit Kumar [1 ]
Khan, Rizwan Hasan [1 ]
机构
[1] Aligarh Muslim Univ, Interdisciplinary Biotechnol Unit, Aligarh 202002, UP, India
关键词
Protein aggregation; Amyloids; Protein misfolding and amyloid inhibitors; ANTI-AMYLOIDOGENIC BEHAVIOR; ALPHA-SYNUCLEIN AGGREGATION; QUALITY-CONTROL; IN-VITRO; MOLECULAR CHAPERONES; CELLULAR STRATEGIES; ALZHEIMERS-DISEASE; BETA OLIGOMERS; FIBRILS; FIBRILLATION;
D O I
10.1016/j.ijbiomac.2017.05.048
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aggregation of specific proteins is hypothesized to cause several pathological conditions, which are collectively known as amyloid disorders. The aggregation of peptides and proteins is mainly associated with the perturbation of cellular function, ageing and various human disorders. Mounting evidence suggests that protein aggregation is often caused by mutation, environmental stress or the cellular response to an imbalanced protein homeostasis. This review summarizes the background information on the protein folding, misfolding, cellular strategies against protein aggregation, factors affecting protein aggregation and mechanism of protein aggregation. We then focus on various inhibitors for protein aggregation both in vitro and in vivo. We conclude with a perspective that better therapeutics could be developed by using cocktail of small molecule inhibitors for the treatment of amyloid diseases. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:208 / 219
页数:12
相关论文
共 145 条
[11]   Amyloidosis-related nephrotic syndrome due to a G654A gelsolin mutation: the first report from the Middle East [J].
Ardalan, Mohammad Reza ;
Shoja, Mohammadali Mohajel ;
Kiuru-Enari, Sari .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (01) :272-275
[12]   In vivo aspects of protein folding and quality control [J].
Balchin, David ;
Hayer-Hartl, Manajit ;
Hartl, F. Ulrich .
SCIENCE, 2016, 353 (6294)
[13]  
BARBU E, 1953, DISCUSS FARADAY SOC, P77
[14]   Effect of Fe3O4 magnetic nanoparticles on lysozyme amyloid aggregation [J].
Bellova, Andrea ;
Bystrenova, Eva ;
Koneracka, Martina ;
Kopcansky, Peter ;
Valle, Francesco ;
Tomasovicova, Natalia ;
Timko, Milan ;
Bagelova, Jaroslava ;
Biscarini, Fabio ;
Gazova, Zuzana .
NANOTECHNOLOGY, 2010, 21 (06) :065103
[15]   Review: Mechanisms of disaggregation and refolding of stable protein aggregates by molecular chaperones [J].
Ben-Zvi, AP ;
Goloubinoff, P .
JOURNAL OF STRUCTURAL BIOLOGY, 2001, 135 (02) :84-93
[16]   3D DOMAIN SWAPPING - A MECHANISM FOR OLIGOMER ASSEMBLY [J].
BENNETT, MJ ;
SCHLUNEGGER, MP ;
EISENBERG, D .
PROTEIN SCIENCE, 1995, 4 (12) :2455-2468
[17]  
Bhargava P, 2017, J ACCOUNTING FINANCE, P1
[18]   The amyloid interactome: Exploring protein aggregation [J].
Biza, Konstantina V. ;
Nastou, Katerina C. ;
Tsiolaki, Paraskevi L. ;
Mastrokalou, Chara V. ;
Hamodrakas, Stavros J. ;
Iconomidou, Vassiliki A. .
PLOS ONE, 2017, 12 (03)
[19]   ER protein quality control and proteasome-mediated protein degradation [J].
Brodsky, JL ;
McCracken, AA .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 1999, 10 (05) :507-513
[20]   Inhibition of IAPP and IAPP(20-29) Fibrillation by Polymeric Nanoparticles [J].
Cabaleiro-Lago, C. ;
Lynch, I. ;
Dawson, K. A. ;
Linse, S. .
LANGMUIR, 2010, 26 (05) :3453-3461